Psoriatic Arthritis: Competitive Landscape to 2026
The Psoriatic Arthritis (PsA) market has become increasingly competitive, with both subcutaneous and intravenous therapies being available as well as two oral small molecule and biosimilars. However, J&J and AbbVie are slated to remain headliners in the psoriatic arthritis marketplace, looking to capitalize on the excitement surrounding interleukin inhibitors and janus kinase inhibitors.
J&J and AbbVie have been the dominant players in the psoriatic arthritis market since the introduction of Remicade (2004) and Humira (2005) as the second and third TNF inhibitors approved by the FDA, respectively. AbbVie and J&J have launched or are developing biologics with novel mechanisms of action, including interleukin inhibitors, maintaining their position in the psoriatic arthritis space.
Diagnosed prevalence cases of psoriatic arthritis is expected to grow across each of the 8MM (United States, Japan, Australia, United Kingdom, France, Italy, Germany, Spain). The US will have the largest growth with almost 470,000 diagnosed prevalent cases in 2016, growing at an AGR of 5.36% to 2026.
It is found that industry sponsors are responsible for over 70% of psoriatic arthritis clinical trials, with the top seven industry sponsors accounting for 64% of all industry sponsored trials. Of these AbbVie and Johnson & Johnson (J&J) are responsible for 47 of the 121 industry sponsored clinical trials in the psoriatic arthritis space.
The report Psoriatic Arthritis: Competitive Landscape to 2026, provides an assessment of the pipeline, clinical, and commercial landscape of psoriatic arthritis. Overall, it is expected that new drug approvals to drive market growth over the next decade (2016-2026).
Reasons to buy
- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment: leading marketed products, current and future players
- Competitive Landscape Analysis: key market events (2016-2026).
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global psoriatic arthritis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global psoriatic arthritis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- 1. Preface
- 1.1 Table of Contents
- 1.2 Abbreviations
- 1.3 Related Reports
- 1.4 Upcoming Related Reports
- 2. Executive Summary
- 2.1 Key Findings
- 2.2 Key Events
- 3. Introduction
- 3.1 Report Scope
- 3.2 Disease Overview and Epidemiology
- 4. Pipeline Assessment
- 4.1 Pipeline Overview
- 4.2 Pipeline Breakdown by Region/Country
- 4.3 Pipeline Breakdown by Molecule Type and Target
- 4.4 Drug Review Designations
- 4.5 Products in Early-Stage Clinical Development
- 5. Clinical Trial Assessment
- 5.1 Clinical Trials Overview
- 5.2 Top Sponsors of Clinical Trials in Psoriatic Arthritis
- 5.3 Trial Breakdown by Region
- 5.4 Therapy Area Perspective
- 5.5 Enrollment Analytics
- 6. Commercial Assessment
- 6.1 Leading Marketed Products
- 6.2 Current & Future Players
- 7. Competitive Landscape Analysis (2016-2026)
- 7.1 Events Classification Overview
- 7.2 US
- 7.3 5EU
- 7.4 Japan
- 7.5 Australia
- 8. Appendix
- 8.1 Sources
- 8.2 Methodology
- 8.3 Key Events Included in the Analysis
- 8.4 About the Authors
- 8.5 About GlobalData
- 8.6 Disclaimer